文献速递老年慢病共病管理多重用药

多重慢性病负担对植入式心律转复除颤器治疗负担及适当性的影响

Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies.
PubMed 文献 · J Am Geriatr Soc · 2019-03-20

本研究为回顾性队列研究,纳入2235例因左心室收缩功能障碍接受植入式心律转复除颤器(ICD)一级预防的成人患者,随访约2.2年。结果显示,多重慢性病负担越高,患者接受不适当ICD治疗的风险越高,而适当治疗风险无显著增加,提示在ICD植入共同决策中应考虑共病负担。

要点

  • 共病负担越高,不适当ICD治疗风险越高(8-16种共病HR 2.91)。
  • 共病负担与适当ICD治疗风险无显著关联。
  • ICD植入共同决策应纳入共病负担评估。

核心结论

  • 在一级预防ICD接受者中,多重慢性病负担独立增加不适当装置治疗风险,但不增加适当治疗风险。

研究设计与样本

  • 回顾性队列研究,纳入美国7个医疗系统2235例左心室收缩功能障碍接受ICD一级预防的成人,平均年龄69±11岁,75%为男性。

主要发现

  • 随访平均2.2年,18.3%患者经历至少一次适当治疗,9.9%经历至少一次不适当治疗。
  • 共病负担4-5种、6-7种、8-16种者首次不适当治疗调整HR分别为1.94(95%CI 1.14-3.31)、2.25(95%CI 1.25-4.05)、2.91(95%CI 1.54-5.50)。
  • 8-16种共病者ICD治疗总负担调整RR=2.12(95%CI 1.43-3.16),不适当治疗负担RR=3.39(95%CI 1.67-6.86),接受不适当vs适当治疗风险RR=1.74(95%CI 1.07-2.82)。
  • 共病负担与适当ICD治疗无显著关联;单独分析电击或抗心动过速起搏治疗时模式相似。

关键数值与推荐

  • 共病负担按24种慢性病数量分为0-3、4-5、6-7、8-16种四组。
  • 中位共病数为6种(四分位距4-8),98%患者至少有两种共病。

临床怎么用

  • 对一级预防ICD候选老年患者,应评估共病负担以识别不适当治疗高风险者。
  • 共病负担可作为ICD植入共同决策的参考因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN: Retrospective cohort study. SETTING: Seven US healthcare delivery systems. PARTICIPANTS: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter-defibrillator (ICD) for primary prevention. MEASUREMENTS: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0-3, 4-5, 6-7 and 8-16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4-8), with 98% having at least two comorbidities. During a mean 2.2 years of follow-up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14-3.31] for 4-5 comorbidities; HR = 2.25 [95% CI = 1.25-4.05] for 6-7 comorbidities; and HR = 2.91 [95% CI = 1.54-5.50] for 8-16 comorbidities). Participants with 8-16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43-3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67-6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07-2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Hajduk AM, Gurwitz JH, Tabada G, et al. Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies. J Am Geriatr Soc. 2019. PMID: 30892695. doi:10.1111/jgs.15839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。